|
||||||
| Home |
| Find a Clinical Trial |
| Clinical Trial FAQs |
| About Informed Consent |
| Clinical Trials Glossary |
| Medical Research Areas |
| Clinical Trial Resources |
|
 |
Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only. | |
|
|
 |
|
|
|
|||
|
Novartis Clinical
Trials provides information about research studies recruiting
within the U.S. Visit ClinicalTrials.gov, a registry of federally and privately supported clinical trial for more information regarding clinical trials outside of the U.S. |
|
|
Find a Clinical Trial
Metastatic Melanoma
Metastatic melanoma is the most advanced stage melanoma--a type of skin cancer. These cancer cells can become malignant and grow uncontrollably. This creates a fast-growing mass of cells, called a tumor.
Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial. For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy. Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.
Malignant Melanoma Study CSTI571BUS255
Novartis Oncology is supporting a clinical study that is being sponsored and conducted by Dr. F. Stephen Hodi of the Dana-Farber Cancer Institute, to find out if the study drug imatinib mesylate (Gleevec®) is safe and effective for people, 18 years of age or older, who have metastatic acral lentiginous melanoma which is a form of skin cancer that commonly appears as a dark patch on the palms, soles, fingers, toes, under fingernails or toenails, or mucous membranes. Gleevec® has been approved for the treatment of certain types of cancers, however it is not approved for metastatic acral lentiginous melanoma.
Trial phase: Phase 2 Participation Duration: Participants will be asked to visit the study center a predetermined number of times over the course of a one year period. Protocol Number: CSTI571BUS255 |